MX2011006764A - Procedimiento y compuestos intermedios para preparar un inhibidor de proteasa macrociclico del vhc. - Google Patents

Procedimiento y compuestos intermedios para preparar un inhibidor de proteasa macrociclico del vhc.

Info

Publication number
MX2011006764A
MX2011006764A MX2011006764A MX2011006764A MX2011006764A MX 2011006764 A MX2011006764 A MX 2011006764A MX 2011006764 A MX2011006764 A MX 2011006764A MX 2011006764 A MX2011006764 A MX 2011006764A MX 2011006764 A MX2011006764 A MX 2011006764A
Authority
MX
Mexico
Prior art keywords
intermediates
preparing
processes
hcv
protease inhibitor
Prior art date
Application number
MX2011006764A
Other languages
English (en)
Inventor
Andras Horvath
Dominique Paul Michel Depre
Dominic John Ormerod
Veronique Cerpentier
Original Assignee
Ortho Mcneil Janssen Pharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Janssen Pharm filed Critical Ortho Mcneil Janssen Pharm
Publication of MX2011006764A publication Critical patent/MX2011006764A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/475—Preparation of carboxylic acid esters by splitting of carbon-to-carbon bonds and redistribution, e.g. disproportionation or migration of groups between different molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C07D453/04—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems having a quinolyl-4, a substituted quinolyl-4 or a alkylenedioxy-quinolyl-4 radical linked through only one carbon atom, attached in position 2, e.g. quinine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Furan Compounds (AREA)

Abstract

La presente invención se refiere a la sal de cinconidina (ver fórmula (XXa)) útil en la preparación de compuestos intermedios para preparar un inhibidor del VHC macrocíclico, así como también se refiere a procedimientos que involucran esta sal.
MX2011006764A 2008-12-23 2009-12-22 Procedimiento y compuestos intermedios para preparar un inhibidor de proteasa macrociclico del vhc. MX2011006764A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08172691 2008-12-23
PCT/EP2009/067715 WO2010072742A1 (en) 2008-12-23 2009-12-22 Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv

Publications (1)

Publication Number Publication Date
MX2011006764A true MX2011006764A (es) 2011-08-03

Family

ID=40548041

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011006764A MX2011006764A (es) 2008-12-23 2009-12-22 Procedimiento y compuestos intermedios para preparar un inhibidor de proteasa macrociclico del vhc.

Country Status (23)

Country Link
US (2) US8927722B2 (es)
EP (1) EP2382198B1 (es)
JP (1) JP5687631B2 (es)
KR (1) KR101734507B1 (es)
CN (1) CN102264715B (es)
AR (1) AR074863A1 (es)
AU (1) AU2009331530B2 (es)
BR (1) BRPI0923393B1 (es)
CA (1) CA2745565C (es)
CY (1) CY1114488T1 (es)
DK (1) DK2382198T3 (es)
ES (1) ES2429013T3 (es)
HK (1) HK1164839A1 (es)
HR (1) HRP20130906T1 (es)
IL (1) IL213246A (es)
MX (1) MX2011006764A (es)
PL (1) PL2382198T3 (es)
PT (1) PT2382198E (es)
RU (1) RU2016120007A (es)
SI (1) SI2382198T1 (es)
SM (1) SMT201300116B (es)
TW (1) TWI461424B (es)
WO (1) WO2010072742A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101734507B1 (ko) 2008-12-23 2017-05-11 얀센 파마슈티칼스 인코포레이티드 Ｈｃｖ의 마크로시클릭 프로테아제 억제제를 제조하기 위한 방법 및 중간체
AR087993A1 (es) * 2011-09-22 2014-04-30 Janssen Pharmaceuticals Inc Procesos e intermediarios para la preparacion de un inhibidor macrociclico de la proteasa del hcv
KR20140086967A (ko) * 2011-10-28 2014-07-08 얀센 파마슈티칼즈, 인코포레이티드 거대고리 프로테아제 저해제 tmc435의 중간체를 제조하는 개선된 방법
CN103387509B (zh) * 2012-05-11 2016-06-08 重庆博腾制药科技股份有限公司 一种hcv蛋白酶抑制剂中间体的制备方法
BR112014030649A2 (pt) 2012-06-08 2017-06-27 Gilead Sciences Inc inibidores macrocíclicos da flaviviridae vírus
AR091279A1 (es) 2012-06-08 2015-01-21 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
BR112014030630A2 (pt) * 2012-06-08 2017-06-27 Gilead Sciences Inc inibidores macrocíclicos de vírus flaviviridae
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
JP6511432B2 (ja) 2013-03-15 2019-05-15 ギリアード サイエンシーズ， インコーポレイテッド Ｃ型肝炎ウイルスの大環状二環式阻害剤
CN105308043B (zh) * 2014-05-29 2018-01-30 杭州普晒医药科技有限公司 丙型肝炎药物的晶型及其制备方法、其药物组合物和用途
MA41812A (fr) 2015-03-27 2018-01-30 Janssen Pharmaceuticals Inc Procédés et intermédiaires pour la préparation d'un inhibiteur de protéase macrocyclique du vhc

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8300536A (nl) 1983-02-14 1984-09-03 Oce Andeno Bv Optisch actief alfa-azido-p-hydroxyfenylazijnzuur en zijn zouten alsmede de bereiding daarvan.
JPS6124539A (ja) 1984-07-11 1986-02-03 Sagami Chem Res Center 光学活性（ｒ）−２，５，１２−トリヒドロキシ−１，２，３，４−テトラヒドロナフタセン−６，１１−ジオン−２−カルボン酸の取得方法
JP4218040B2 (ja) 1997-12-26 2009-02-04 曽田香料株式会社 有機酸とアミンの複合塩の製造法
JP3844112B2 (ja) 2000-08-23 2006-11-08 高砂香料工業株式会社 ３，５，６−トリヒドロキシヘキサン酸アンモニウム塩誘導体、及びその製造方法
US7608590B2 (en) 2004-01-30 2009-10-27 Medivir Ab HCV NS-3 serine protease inhibitors
CN101146794A (zh) 2005-01-21 2008-03-19 阿斯泰克斯治疗有限公司 用于抑制cdk和gsk的吡唑衍生物
US8012939B2 (en) * 2005-07-29 2011-09-06 Tibotec Pharmaceuticals Ltd. Co Macrocyclic inhibitors of hepatitis C virus
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
TWI455936B (zh) * 2007-02-01 2014-10-11 Tibotec Pharm Ltd 用於製備ｈｃｖ之大環蛋白酶抑制劑之方法及中間物
KR20090111326A (ko) * 2007-02-08 2009-10-26 티보텍 파마슈티칼즈 리미티드 Ｈｃｖ 억제 마크로사이클릭 페닐카바메이트
KR101734507B1 (ko) 2008-12-23 2017-05-11 얀센 파마슈티칼스 인코포레이티드 Ｈｃｖ의 마크로시클릭 프로테아제 억제제를 제조하기 위한 방법 및 중간체

Also Published As

Publication number Publication date
CA2745565C (en) 2017-03-07
JP2012513381A (ja) 2012-06-14
JP5687631B2 (ja) 2015-03-18
US20110257403A1 (en) 2011-10-20
BRPI0923393A2 (pt) 2015-07-28
DK2382198T3 (da) 2013-09-30
RU2016120007A (ru) 2018-11-13
US9115077B2 (en) 2015-08-25
PT2382198E (pt) 2013-10-01
EP2382198B1 (en) 2013-07-10
AU2009331530A1 (en) 2011-06-23
AU2009331530B2 (en) 2015-04-09
BRPI0923393B1 (pt) 2018-06-19
KR20110099048A (ko) 2011-09-05
EP2382198A1 (en) 2011-11-02
IL213246A0 (en) 2011-07-31
US8927722B2 (en) 2015-01-06
US20150080577A1 (en) 2015-03-19
IL213246A (en) 2017-10-31
ES2429013T3 (es) 2013-11-12
CY1114488T1 (el) 2016-10-05
TW201033205A (en) 2010-09-16
HK1164839A1 (zh) 2012-09-28
CA2745565A1 (en) 2010-07-01
SMT201300116B (it) 2013-11-08
RU2011130895A (ru) 2013-01-27
CN102264715B (zh) 2015-12-02
HRP20130906T1 (hr) 2013-10-25
TWI461424B (zh) 2014-11-21
SI2382198T1 (sl) 2013-11-29
KR101734507B1 (ko) 2017-05-11
PL2382198T3 (pl) 2013-11-29
AR074863A1 (es) 2011-02-16
CN102264715A (zh) 2011-11-30
WO2010072742A1 (en) 2010-07-01

Similar Documents

Publication Publication Date Title
MX2011006764A (es) Procedimiento y compuestos intermedios para preparar un inhibidor de proteasa macrociclico del vhc.
HUS1700039I1 (hu) Makrociklusos prolinból leszármaztatható HCV szerin proteáz inhibitorok
WO2011002808A8 (en) Hcv protease inhibitors and uses thereof
CA2830549C (en) Methods and compositions for preparing noribogaine from voacangine
WO2010111436A3 (en) Antiviral compounds and uses thereof
MX2011011272A (es) Procesos e intermediarios.
WO2012136383A8 (en) Preparation of sitagliptin intermediates
WO2012082672A3 (en) Process and intermediates for preparing macrolactams
MY155330A (en) Methods for salt production
ZA200808046B (en) Process for preparation of HIV protease inhibitors
MX2012007341A (es) Inhibidores de proteasoma y procesos para su preparacion, purificacion y uso.
TW200728310A (en) Process for the preparation of ferri-succinylcasein
WO2011004402A3 (en) Improved process for the preparation of ambrisentan and novel intermediates thereof
WO2010015656A3 (en) Alkoxypyrazoles and the process for their preparation
AU2012248013B2 (en) Intermediate for synthesizing caspofungin and preparation method therefor
UA110626C2 (uk) Спосіб одержання пан-інгібіторів циклінзалежної кінази формули (i), а також проміжні продукти цього процесу одержання
WO2010059916A3 (en) Preparation of docetaxel
MX2010001962A (es) Procedimiento para preparar 4-aminobut-2-enolidos.
WO2010027889A3 (en) Process for synthesizing substituted isoquinolines
UA34487U (en) Aquananomagnesium
TW200728267A (en) Processes and intermediates for the preparation of prostaglandins
WO2008111018A3 (en) Process for the preparation of crystals of prulifloxacin
WO2009112149A3 (de) Verfahren zur reinigung therapeutischer proteine mittels mehrstufiger extraktion
MX2009003196A (es) Proceso para la preparacion de y-butirolactonas.
TW200637495A (en) Novel composite for inhibiting algae growth and use thereof

Legal Events

Date Code Title Description
FG Grant or registration